The global antibiotic drugs market was valued at US$ 43.6 billion in 2022 and is expected to reach US$ 64.9 billion by 2033. The sales of antibiotic drugs are set to gain traction over the forecast years with a CAGR of around 3.7%.
| Attributes | Key Statistics |
|---|---|
| Market Value (2022) | US$ 43.6 billion |
| Market Value (2023) | US$ 45.0 billion |
| Market Value (2033) | US$ 64.9 billion |
| Estimated Growth (2023 to 2033) | 3.7 % CAGR |
| Share of Top 5 Countries | 66.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Emergence of Infectious Diseases
Expansion in Product Portfolio
The antibiotic drugs market exhibited a CAGR of 2.9% between 2017 and 2022. In 2022, the global market for anti-infective medicines accounted for around US$ 76.7 billion, of which antibiotics have a share of US$ 43.6 billion.
| Attributes | Key Statistics |
|---|---|
| Market Value (2021) | US$ 42.3 billion |
| Estimated Growth (2017 to 2022) | 2.90 % CAGR |
The rising antibiotic treatment for bacterial infections to prevent them from spreading has spurred the global demand for antibiotics. In India, the percentage of single antibiotics consumption is around 4.1 billion, according to the National Library of Medicine. The WHO report on antibiotic usage surveillance, published in 2018, examined data from 65 countries. As determined by daily dosages per 1,000 inhabitants with a rate of 64.4, Mongolia had the most prominent consumption. At 4.4, Burundi received the lowest score. The most popular antibiotics consumed were amoxicillin and amoxicillin/clavulanic acid.
Principal Consultant
New entity development is more time- and money-consuming; it can take a substantial financial burden and several years to complete. Therefore, it is anticipated that the market for antibiotics can be hampered by the high cost of medication research and the rigorous regulatory approval process.
Adverse effects might result from inadequate knowledge of antibiotic administration and the indiscriminate use of antibiotics for minor infections. As a result, it is anticipated that the growing demand for antibiotics will be hampered by the increased side effects brought on by the emergence of resistance and other adverse side effects. For instance, taking a quinolone antibiotic and a systemic corticosteroid may cause tendon injury.
Antibiotic-resistant microorganisms have emerged due to improper antibiotic use and misuse. Antibiotics' potential danger goes beyond the development of antimicrobial resistance, and excessive use of them is linked to adverse consequences on patients, which are particularly obvious in critically ill patients in intensive care units.
Antibiotics are frequently administered to treat illnesses or symptoms that don't react to them or are likely to go away on their own. Additionally, inappropriate or inadequate antibiotics are administered for some bacterial illnesses. Therefore, these factors contribute to the restraint of the growth of the antibiotic drugs market.
| Top Countries | CAGR |
|---|---|
| United States | 12.1% |
| China | 8.2% |
| India | 6.1% |
| United Kingdom | 4.3% |
| Germany | 3.1% |
The United States is dominating the antibiotic drugs market with a share of 12.1%. The market was valued at US$ 5.1 billion in 2022.
The American healthcare system is renowned for its high costs and sophisticated infrastructure. The United States government and regulatory authorities are implementing a variety of cost-effective healthcare schemes to curb catheter-associated UTIs and other infectious diseases. Furthermore, there is a growing need for antibiotics as a result of the increased occurrence of ventilator-associated infections.
According to the Centers for Disease Control and Prevention (CDC), more than 2.8 billion antimicrobial-resistant illnesses occur in the United States each year, resulting in more than 35,000 deaths. The United States government is undertaking several preventative and infection control strategies to reduce the number of illnesses and fatalities caused by antibiotic-resistant bacteria. The United States market for antibiotics is now experiencing significant growth opportunities.
China is an emerging antibiotic drug market with a market share of 8.2%, with a valuation of US$ 3.4 billion in 2022.
The pharmaceutical market in China is the second-leading in the world and is further expanding rapidly. China's OTC pharmaceutical business is still enticing, with a sizable market share. According to OEC (Observatory of Economic Complexity), China was the world's top supplier of antibiotics in 2020, with shipments amounting to US$ 3.98 billion.
The healthcare industry in China has expanded significantly, allowing it to transition from a base for the production of pharmaceuticals to a vital research and development center. As a result, China has strengthened its position as a strategic player in the global pharmaceutical industry, acting as a foundation for increasing research and development while also functioning as a consumer nation. With all these factors combined, the market of antibiotic drugs in China is one of the emerging and lucrative markets.
India is an emerging market and accounted for a market share of more than 6.1% in 2022.
In recent years, small and leading biopharmaceutical businesses in India have relied on the contract research organization (CRO) industry to supply research services to their R&D operations. However, as the majority of medicines in the pipeline are predicted to reach the end stage and be commercialized by the end of the decade, it is anticipated that the need for antibiotics will rise.
Due to the existence of multiple government-funded medical and pharmaceutical institutions with state-of-the-art equipment, clinical trials and research are now a significant industry in India. For multi-centered clinical studies, these facilities are appropriate. These factors are making India one of the new emerging antibiotic drug markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Penicillin-based products dominate the market for antibiotics worldwide. The penicillin antibiotics segment is anticipated to rule the worldwide antibiotics market throughout the forecast period.
| Top Product Type | Penicillins |
|---|---|
| CAGR | 3.6% |
The acceptance of penicillin as a first-line antibiotic therapy and the rising demand for antibiotics to treat various bacterial infections are expected to increase the need for penicillin globally.
People typically contract an infection by contacting infected individuals, eating or drinking contaminated food or water (sometimes called food poisoning), or handling contaminated objects like cutlery, taps, toys, etc.
| Top Indication | Gastrointestinal Infections |
|---|---|
| CAGR | 3.5% |
This results in an increased prevalence of gastrointestinal infection or gastroenteritis. Hence, it had a market share of 26.0% in 2022.
The parenteral route of drug administration occupied 68.6% of global market share in 2022. Intravenous (IV), intramuscular (IM), and subcutaneous parenteral methods are the most significant and often utilized parenteral routes (SC).
| Top Route of Administration | Parenteral |
|---|---|
| CAGR | 3.5% |
For medications with limited GIT absorption and medicines like insulin that are unstable in the GIT, the parenteral route of drug administration is the preferred method.
To expand their product offerings and boost the competitiveness of their companies, the key market participants focus on introducing several effective medications and winning regulatory body clearance. Additionally, businesses are increasingly focusing on expanding their business globally by setting up new labs and facilities to enhance their market presence.
Recent Development
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; the Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, South Africa, North Africa, and GCC Countries. |
| Key Segments Covered | Drug Class, Indication, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Abbott Laboratories; AbbVie; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Merck & Co. Inc.; Mylan N.V.; Novartis International AG (Sandoz); Sanofi; Teva Pharmaceutical Industries Ltd.; Melinta Therapeutics; Pfizer Inc; Basilea Pharmaceutica Ltd.; Tetraphase Pharmaceuticals; Paratek Pharmaceuticals, Inc.; Nabriva Therapeutics plc; Spero Therapeutics |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global market is likely to be worth US$ 45 billion in 2023.
The market is expected to reach US$ 64.9 billion by 2033.
North America holds 23.9% of the global market in 2022, with the United States being the leading contributor.
China's market is offering lucrative growth, with a market share of 8.2% in 2022.
The United States, China, India, the United Kingdom, and Germany are the top 5 countries.
From 2017 to 2022, the market for antibiotic drugs expanded at the rate of 2.9%.
Pfizer, Sanofi SA, AbbVie Inc. (Allergan plc), Teva Pharmaceuticals, GlaxoSmithKline plc, Novartis AG, Abbott Laboratories, etc.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Brand Mapping Analysis 3.1. Price v/s Drug Class 3.2. Value for Money 3.3. Top of Mind Antibiotics Brands 3.4. Brand Portfolio-by Key Players 3.5. Brand Loyalty Mapping 3.6. Route of Administration Pattern Overview 3.7. Branded vs Unbranded-Market Mix 4. Distribution Channel Wise Key Brand Positioning 4.1. Global Top Retailers and their Brand Offerings 4.1.1. Retail Pharmacies 4.1.2. Hospital Pharmacies 4.1.3. Online Pharmacies 4.2. Retail Pricing Strategies 5. Consumer Buying Behavior Analysis 5.1. Functionality and Drug Demand 5.1.1. Penicillins 5.1.2. Fluoroquinolones 5.1.3. Cephalosporins 5.1.4. Macrolides 5.1.5. Others 5.2. What factors do you consider when deciding to purchase antibiotics? 5.3. How important are product certifications when choosing antibiotics? 5.4. How important is the brand reputation and recognition when selecting antibiotics? 5.5. What marketing channels do you prefer for learning about new antibiotics? 5.6. How often do you purchase new antibiotics? 5.6.1. Once or More Every Month 5.6.2. Once Every 2 months 5.6.3. Once Every 6 Months 5.6.4. Once a Year 5.7. Less Than Once A Year 6. Key Market Trends 6.1. Key Trends Impacting the Market 6.2. Drug class Innovation / Development Trends 7. Key Success Factors 7.1. Disease Epidemiology 7.2. Recent Product Launches 7.3. Regulatory Scenario 7.4. Product Adoption Analysis 7.5. Patient Treatment Journey 7.6. PESTLE Analysis 7.7. Porters Analysis 7.8. Key Promotional Strategies by Key Manufacturers 8. Market Background 8.1. Macro-Economic Factors 8.1.1. Global GDP Growth Outlook 8.1.2. Global Healthcare Spending Outlook 8.1.3. Global Anti-Infective Drugs Market Outlook 8.2. Forecast Factors - Relevance & Impact 8.2.1. Increasing Cases of Allergic Reactions 8.2.2. Rising Adoption of Anti-pyretic 8.2.3. Increase in Research and Development spending 8.2.4. Increase Drug Discovery activity 8.2.5. Approval of New Drug class 8.2.6. Strategical Mergers and Acquisitions Among Key Players 8.3. Market Dynamics 8.3.1. Drivers 8.3.2. Restraints 8.3.3. Opportunity Analysis 9. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 9.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug class 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million), By Drug class, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Drug class, 2023 to 2033 10.3.1. Penicillins 10.3.2. Fluoroquinolones 10.3.3. Cephalosporins 10.3.4. Macrolides 10.3.5. Others 10.4. Market Attractiveness Analysis By Drug class 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million), By Indication, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Indication, 2023 to 2033 11.3.1. Dermatological Infections 11.3.2. Respiratory Infections 11.3.3. Urinary Tract Infections 11.3.4. Ear Infections 11.3.5. Gastrointestinal Infections 11.3.6. Others 11.4. Market Attractiveness Analysis, By Indication 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million), By Route of Administration, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Route of Administration, 2023 to 2033 12.3.1. Oral 12.3.2. Parenteral 12.4. Market Attractiveness Analysis, By Route of Administration 13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million), By Distribution Channel, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) and Forecast By Distribution Channel, 2023 to 2033 13.3.1. Retail Pharmacies 13.3.2. Hospital Pharmacies 13.3.3. Online pharmacies 13.4. Market Attractiveness Analysis By Distribution Channel 14. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) and Forecast By Region, 2023 to 2033 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. East Asia 14.3.5. South Asia 14.3.6. Oceania 14.3.7. Middle East and Africa (MEA) 14.4. Market Attractiveness Analysis By Region 15. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. USA 15.3.1.2. Canada 15.3.2. By Drug class 15.3.3. By Indication 15.3.4. By Route of Administration 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug class 15.4.3. By Indication 15.4.4. By Route of Administration 15.4.5. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. USA Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Drug class 15.8.1.2.2. By Indication 15.8.1.2.3. By Route of Administration 15.8.1.2.4. By Distribution Channel 15.8.2. Canada Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Drug class 15.8.2.2.2. By Indication 15.8.2.2.3. By Route of Administration 15.8.2.2.4. By Distribution Channel 16. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Mexico 16.3.1.2. Brazil 16.3.1.3. Argentina 16.3.1.4. Rest of Latin America 16.3.2. By Drug class 16.3.3. By Indication 16.3.4. By Route of Administration 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug class 16.4.3. By Indication 16.4.4. By Route of Administration 16.4.5. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. Mexico Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Drug class 16.8.1.2.2. By Indication 16.8.1.2.3. By Route of Administration 16.8.1.2.4. By Distribution Channel 16.8.2. Brazil Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Drug class 16.8.2.2.2. By Indication 16.8.2.2.3. By Route of Administration 16.8.2.2.4. By Distribution Channel 16.8.3. Argentina Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Drug class 16.8.3.2.2. By Indication 16.8.3.2.3. By Route of Administration 16.8.3.2.4. By Distribution Channel 17. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. Italy 17.3.1.3. France 17.3.1.4. UK 17.3.1.5. Spain 17.3.1.6. BENELUX 17.3.1.7. Russia 17.3.1.8. Rest of Europe 17.3.2. By Drug class 17.3.3. By Indication 17.3.4. By Route of Administration 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug class 17.4.3. By Indication 17.4.4. By Route of Administration 17.4.5. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Germany Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Drug class 17.8.1.2.2. By Indication 17.8.1.2.3. By Route of Administration 17.8.1.2.4. By Distribution Channel 17.8.2. Italy Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Drug class 17.8.2.2.2. By Indication 17.8.2.2.3. By Route of Administration 17.8.2.2.4. By Distribution Channel 17.8.3. France Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Drug class 17.8.3.2.2. By Indication 17.8.3.2.3. By Route of Administration 17.8.3.2.4. By Distribution Channel 17.8.4. UK Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Drug class 17.8.4.2.2. By Indication 17.8.4.2.3. By Route of Administration 17.8.4.2.4. By Distribution Channel 17.8.5. Spain Market Analysis 17.8.5.1. Introduction 17.8.5.2. Market Analysis and Forecast by Market Taxonomy 17.8.5.2.1. By Drug class 17.8.5.2.2. By Indication 17.8.5.2.3. By Route of Administration 17.8.5.2.4. By Distribution Channel 17.8.6. BENELUX Market Analysis 17.8.6.1. Introduction 17.8.6.2. Market Analysis and Forecast by Market Taxonomy 17.8.6.2.1. By Drug class 17.8.6.2.2. By Indication 17.8.6.2.3. By Route of Administration 17.8.6.2.4. By Distribution Channel 17.8.7. Nordic Countries Market Analysis 17.8.7.1. Introduction 17.8.7.2. Market Analysis and Forecast by Market Taxonomy 17.8.7.2.1. By Drug class 17.8.7.2.2. By Indication 17.8.7.2.3. By Route of Administration 17.8.7.2.4. By Distribution Channel 17.8.8. Russia Market Analysis 17.8.8.1. Introduction 17.8.8.2. Market Analysis and Forecast by Market Taxonomy 17.8.8.2.1. By Drug class 17.8.8.2.2. By Indication 17.8.8.2.3. By Route of Administration 17.8.8.2.4. By Distribution Channel 18. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. China 18.3.1.2. Japan 18.3.1.3. South Korea 18.3.2. By Drug class 18.3.3. By Indication 18.3.4. By Route of Administration 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug class 18.4.3. By Indication 18.4.4. By Route of Administration 18.4.5. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. China Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Drug class 18.8.1.2.2. By Indication 18.8.1.2.3. By Route of Administration 18.8.1.2.4. By Distribution Channel 18.8.2. Japan Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Drug class 18.8.2.2.2. By Indication 18.8.2.2.3. By Route of Administration 18.8.2.2.4. By Distribution Channel 18.8.3. South Korea Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Drug class 18.8.3.2.2. By Indication 18.8.3.2.3. By Route of Administration 18.8.3.2.4. By Distribution Channel 19. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. India 19.3.1.2. Indonesia 19.3.1.3. Malaysia 19.3.1.4. Thailand 19.3.1.5. Rest of South Asia 19.3.2. By Drug class 19.3.3. By Indication 19.3.4. By Route of Administration 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug class 19.4.3. By Indication 19.4.4. By Route of Administration 19.4.5. By Distribution Channel 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. India Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Drug class 19.8.1.2.2. By Indication 19.8.1.2.3. By Route of Administration 19.8.1.2.4. By Distribution Channel 19.8.2. Indonesia Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Drug class 19.8.2.2.2. By Indication 19.8.2.2.3. By Route of Administration 19.8.2.2.4. By Distribution Channel 19.8.3. Malaysia Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Drug class 19.8.3.2.2. By Indication 19.8.3.2.3. By Route of Administration 19.8.3.2.4. By Distribution Channel 19.8.4. Thailand Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Drug class 19.8.4.2.2. By Indication 19.8.4.2.3. By Route of Administration 19.8.4.2.4. By Distribution Channel 20. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. Australia 20.3.1.2. New Zealand 20.3.2. By Drug class 20.3.3. By Indication 20.3.4. By Route of Administration 20.3.5. By Distribution Channel 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Drug class 20.4.3. By Indication 20.4.4. By Route of Administration 20.4.5. By Distribution Channel 20.5. Market Trends 20.6. Key Market Participants - Intensity Mapping 20.7. Drivers and Restraints - Impact Analysis 20.8. Country Level Analysis & Forecast 20.8.1. Australia Market Analysis 20.8.1.1. Introduction 20.8.1.2. Market Analysis and Forecast by Market Taxonomy 20.8.1.2.1. By Drug class 20.8.1.2.2. By Indication 20.8.1.2.3. By Route of Administration 20.8.1.2.4. By Distribution Channel 20.8.2. New Zealand Market Analysis 20.8.2.1. Introduction 20.8.2.2. Market Analysis and Forecast by Market Taxonomy 20.8.2.2.1. By Drug class 20.8.2.2.2. By Indication 20.8.2.2.3. By Route of Administration 20.8.2.2.4. By Distribution Channel 21. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 21.1. Introduction 21.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022 21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 21.3.1. By Country 21.3.1.1. GCC Countries 21.3.1.2. Türkiye 21.3.1.3. South Africa 21.3.1.4. North Africa 21.3.1.5. Rest of Middle East and Africa 21.3.2. By Drug class 21.3.3. By Indication 21.3.4. By Route of Administration 21.3.5. By Distribution Channel 21.4. Market Attractiveness Analysis 21.4.1. By Country 21.4.2. By Drug class 21.4.3. By Indication 21.4.4. By Route of Administration 21.4.5. By Distribution Channel 21.5. Market Trends 21.6. Key Market Participants - Intensity Mapping 21.7. Drivers and Restraints - Impact Analysis 21.8. Country Level Analysis & Forecast 21.8.1. GCC Countries Market Analysis 21.8.1.1. Introduction 21.8.1.2. Market Analysis and Forecast by Market Taxonomy 21.8.1.2.1. By Drug class 21.8.1.2.2. By Indication 21.8.1.2.3. By Route of Administration 21.8.1.2.4. By Distribution Channel 21.8.2. Türkiye Market Analysis 21.8.2.1. Introduction 21.8.2.2. Market Analysis and Forecast by Market Taxonomy 21.8.2.2.1. By Drug class 21.8.2.2.2. By Indication 21.8.2.2.3. By Route of Administration 21.8.2.2.4. By Distribution Channel 21.8.3. South Africa Market Analysis 21.8.3.1. Introduction 21.8.3.2. Market Analysis and Forecast by Market Taxonomy 21.8.3.2.1. By Drug class 21.8.3.2.2. By Indication 21.8.3.2.3. By Route of Administration 21.8.3.2.4. By Distribution Channel 21.8.4. North Africa Market Analysis 21.8.4.1. Introduction 21.8.4.2. Market Analysis and Forecast by Market Taxonomy 21.8.4.2.1. By Drug class 21.8.4.2.2. By Indication 21.8.4.2.3. By Route of Administration 21.8.4.2.4. By Distribution Channel 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis of Top Players 22.3. Market Concentration 22.4. Market Presence Analysis 22.4.1. Regional Footprint Analysis 22.4.2. Drug class Footprint Analysis 22.4.3. Channel Footprint Analysis 23. Competition Analysis 23.1. Competition Dashboard 23.2. Competition Benchmarking 23.3. Competition Deep Dive 23.3.1. Abbott Laboratries 23.3.1.1. Overview 23.3.1.2. Drug class Portfolio 23.3.1.3. Sales Footprint 23.3.1.4. Key Developments 23.3.1.5. SWOT Analysis 23.3.1.6. Strategy Overview 23.3.1.6.1. Marketing Strategies 23.3.1.6.2. Drug class Strategies 23.3.1.6.3. Channel Strategies 23.3.2. Allergan Plc., 23.3.2.1. Overview 23.3.2.2. Drug class Portfolio 23.3.2.3. Sales Footprint 23.3.2.4. Key Developments 23.3.2.5. SWOT Analysis 23.3.2.6. Strategy Overview 23.3.2.6.1. Marketing Strategies 23.3.2.6.2. Drug class Strategies 23.3.2.6.3. Channel Strategies 23.3.3. F. Hoffmann-La Roche Ltd., 23.3.3.1. Overview 23.3.3.2. Drug class Portfolio 23.3.3.3. Sales Footprint 23.3.3.4. Key Developments 23.3.3.5. SWOT Analysis 23.3.3.6. Strategy Overview 23.3.3.6.1. Marketing Strategies 23.3.3.6.2. Drug class Strategies 23.3.3.6.3. Channel Strategies 23.3.4. GlaxoSmithKline plc, 23.3.4.1. Overview 23.3.4.2. Drug class Portfolio 23.3.4.3. Sales Footprint 23.3.4.4. Key Developments 23.3.4.5. SWOT Analysis 23.3.4.6. Strategy Overview 23.3.4.6.1. Marketing Strategies 23.3.4.6.2. Drug class Strategies 23.3.4.6.3. Channel Strategies 23.3.5. Merck & Co. Inc., 23.3.5.1. Overview 23.3.5.2. Drug class Portfolio 23.3.5.3. Sales Footprint 23.3.5.4. Key Developments 23.3.5.5. SWOT Analysis 23.3.5.6. Strategy Overview 23.3.5.6.1. Marketing Strategies 23.3.5.6.2. Drug class Strategies 23.3.5.6.3. Channel Strategies 23.3.6. Mylan N.V., 23.3.6.1. Overview 23.3.6.2. Drug class Portfolio 23.3.6.3. Sales Footprint 23.3.6.4. Key Developments 23.3.6.5. SWOT Analysis 23.3.6.6. Strategy Overview 23.3.6.6.1. Marketing Strategies 23.3.6.6.2. Drug class Strategies 23.3.6.6.3. Channel Strategies 23.3.7. Novartis International AG (Sandoz), 23.3.7.1. Overview 23.3.7.2. Drug class Portfolio 23.3.7.3. Sales Footprint 23.3.7.4. Key Developments 23.3.7.5. SWOT Analysis 23.3.7.6. Strategy Overview 23.3.7.6.1. Marketing Strategies 23.3.7.6.2. Drug class Strategies 23.3.7.6.3. Channel Strategies 23.3.8. Pfizer Inc., Sanofi, 23.3.8.1. Overview 23.3.8.2. Drug class Portfolio 23.3.8.3. Sales Footprint 23.3.8.4. Key Developments 23.3.8.5. SWOT Analysis 23.3.8.6. Strategy Overview 23.3.8.6.1. Marketing Strategies 23.3.8.6.2. Drug class Strategies 23.3.8.6.3. Channel Strategies 23.3.9. Teva Pharmaceutical Industries Ltd. 23.3.9.1. Overview 23.3.9.2. Drug class Portfolio 23.3.9.3. Sales Footprint 23.3.9.4. Key Developments 23.3.9.5. SWOT Analysis 23.3.9.6. Strategy Overview 23.3.9.6.1. Marketing Strategies 23.3.9.6.2. Drug class Strategies 23.3.9.6.3. Channel Strategies 23.3.10. Melinta Therapeutics 23.3.10.1. Overview 23.3.10.2. Drug class Portfolio 23.3.10.3. Sales Footprint 23.3.10.4. Key Developments 23.3.10.5. SWOT Analysis 23.3.10.6. Strategy Overview 23.3.10.6.1. Marketing Strategies 23.3.10.6.2. Drug class Strategies 23.3.10.6.3. Channel Strategies 23.3.11. Pfizer Inc, 23.3.11.1. Overview 23.3.11.2. Drug class Portfolio 23.3.11.3. Sales Footprint 23.3.11.4. Key Developments 23.3.11.5. SWOT Analysis 23.3.11.6. Strategy Overview 23.3.11.6.1. Marketing Strategies 23.3.11.6.2. Drug class Strategies 23.3.11.6.3. Channel Strategies 23.3.12. Basilea Pharmaceutica Ltd. 23.3.12.1. Overview 23.3.12.2. Drug class Portfolio 23.3.12.3. Sales Footprint 23.3.12.4. Key Developments 23.3.12.5. SWOT Analysis 23.3.12.6. Strategy Overview 23.3.12.6.1. Marketing Strategies 23.3.12.6.2. Drug class Strategies 23.3.12.6.3. Channel Strategies 23.3.13. Tetraphase Pharmaceuticals 23.3.13.1. Overview 23.3.13.2. Drug class Portfolio 23.3.13.3. Sales Footprint 23.3.13.4. Key Developments 23.3.13.5. SWOT Analysis 23.3.13.6. Strategy Overview 23.3.13.6.1. Marketing Strategies 23.3.13.6.2. Drug class Strategies 23.3.13.6.3. Channel Strategies 23.3.14. Paratek Pharmaceuticals, Inc. 23.3.14.1. Overview 23.3.14.2. Drug class Portfolio 23.3.14.3. Sales Footprint 23.3.14.4. Key Developments 23.3.14.5. SWOT Analysis 23.3.14.6. Strategy Overview 23.3.14.6.1. Marketing Strategies 23.3.14.6.2. Drug class Strategies 23.3.14.6.3. Channel Strategies 23.3.15. Nabriva Therapeutics plc 23.3.15.1. Overview 23.3.15.2. Drug class Portfolio 23.3.15.3. Sales Footprint 23.3.15.4. Key Developments 23.3.15.5. SWOT Analysis 23.3.15.6. Strategy Overview 23.3.15.6.1. Marketing Strategies 23.3.15.6.2. Drug class Strategies 23.3.15.6.3. Channel Strategies 23.3.16. Spero Therapeutics 23.3.16.1. Overview 23.3.16.2. Drug class Portfolio 23.3.16.3. Sales Footprint 23.3.16.4. Key Developments 23.3.16.5. SWOT Analysis 23.3.16.6. Strategy Overview 23.3.16.6.1. Marketing Strategies 23.3.16.6.2. Drug class Strategies 23.3.16.6.3. Channel Strategies 24. Assumptions and Acronyms Used 25. Research Methodology
Healthcare
June 2023
REP-GB-13025
273 pages
Explore Healthcare Insights
View Reports
Antibiotic Drug Market
